logo
  

Bayer HealthCare Extends Clinical Investigation Of Xarelto

Bayer HealthCare, a subgroup of Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) and its development partner Janssen Pharmaceuticals, Inc. announced the initiation of the CALLISTO Clinical Research Programme to explore the potential benefits of the oral Factor Xa inhibitor Xarelto (rivaroxaban) for the prevention and treatment of pulmonary embolism and deep vein thrombosis in patients with various types of cancer.

In patients with active cancer, the risk of VTE is four to seven times higher than in people of the same age without cancer. And importantly, chemotherapy significantly increases the risk further by up to 6.5 times. Despite this, none of the current Clinical Guidelines recommend the routine use of VTE prevention in most ambulatory cancer patients. Regarding the use of anticoagulation therapy for the treatment and secondary prevention of VTE, current Clinical Guideline recommendations are based on few and small clinical trials.

The CALLISTO Programme is a multi-trial prospective clinical research initiative aimed at generating new evidence to help manage cancer-associated thrombosis (CAT). The Programme will consist of nine initiatives in total, comprising both clinical studies and Registries, and will involve more than 4,000 patients worldwide.

The CALLISTO Clinical Research Programme will add to the overall investigation of rivaroxaban, which - by the time of its completion - is expected to include more than 275,000 patients in both clinical trials and real world settings.

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto. Xarelto is approved for seven indications, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel oral anticoagulant.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A multi-state listeria outbreak that has killed one and sickened at least 23 others has been linked to Florida -based Big Olaf Creamery brand ice cream, according to the Centers for Disease Control and Prevention or CDC. The outbreak strain has been reported from 10 states, resulting in 22 hospitalizations. One death has been reported from Illinois. Natreve, a premium wellness company, is recalling certain Vegan Protein Powder due to undeclared milk, a known allergen, the U.S. Food and Drug Administration said. The recall involves specific batches of its Vegan Protein Powder French Vanilla Wafer Sundae flavor. The impacted products are stored in 13 oz (10 servings) and 1.47lb (18 servings) white tubs. The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to
RELATED NEWS
Follow RTT